Evidence map›Paper›PMID 40247099›Full record

Articlenpj antimicrobials and resistance2025

Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates.

Christopher Zajac, Nancy E Scott, Susan Kline, Serin E Erayil, Anna Selmecki

Abstract read
In one paragraph

Article in npj antimicrobials and resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Natural product based approaches to overcomeFrontiers in antibiotics · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher ZajacDepartment of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Nancy E ScottDepartment of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Susan KlineDepartment of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Serin E ErayilDepartment of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Anna SelmeckiDepartment of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA. selmecki@umn.edu.ORCID http://orcid.org/0000-0003-3298-2400

Funding

Aneuploidy and Acquired Antifungal Drug Resistance in Candida speciesR01AI143689 · NIAID · UNIVERSITY OF MINNESOTA · PI Anna M. Selmecki · 2020 to 2026
$3.2M
Burroughs Wellcome Fund 1020388National Science Foundation DBI-232051NIAID NIH HHS R01 AI143689NIH HHS R01 AI143689
6 · The paper itself

Abstract

Candida glabrata (Nakaseomyces glabratus) is the most common cause of drug-resistant candidemia and is associated with a high mortality rate. Only a few mechanisms of drug resistance are known in C. glabrata, predominantly involving recurrent single nucleotide polymorphisms. The importance of structural variation in acquired drug resistance is not understood. We performed comparative phenotypic and genomic analyses of six serial bloodstream isolates of C. glabrata and identified novel mutations associated with resistance to echinocandins. Critically, we identified a novel gene conversion event between the hotspot 2 regions of FKS1 and FKS2 that was associated with increased resistance to micafungin. We further analyzed 621 publicly available C. glabrata genomes and found three additional examples of structural variation involving FKS1 and FKS2. Ultimately, drug resistance in C. glabrata involves structural variants that are missed with current diagnostic methods and need to be considered when designing and implementing more effective antifungal management strategies.

Identifiers

PMID40247099
PMCPMC12006411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.